Patents by Inventor Xavier CHAUCHET

Xavier CHAUCHET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD28 BISPECIFIC ANTIBODIES FOR TARGETED T CELL ACTIVATION
    Publication number: 20240002544
    Abstract: The present invention relates to antibody arms which bind agonistically to human CD28. The present invention relates to bispecific antibodies which bind to human carcinoembryonic antigen (CEA) and human CD28 using the agonist anti-CD28 arms described herein. The present invention relates to bispecific antibodies which bind to human mesothelin (MSLN) and human CD28 using the agonist anti-CD28 arms described herein.
    Type: Application
    Filed: March 7, 2023
    Publication date: January 4, 2024
    Inventors: Sara MAJOCCHI, Krzysztof MASTERNAK, Limin SHANG, Nicolas FISCHER, Xavier CHAUCHET
  • BISPECIFIC ANTIBODIES TARGETING CD47 AND PD-L1 AND METHODS OF USE THEREOF
    Publication number: 20220315654
    Abstract: This disclosure provides novel bispecific antibodies that specifically bind to CD47 and Programmed Death-Ligand 1 (PD-L1). The disclosure further relates to methods of making the bispecific antibodies and nucleic acids encoding the antibodies. The disclosure further relates to therapeutic methods for use of the bispecific antibodies in the treatment of a condition associated with malignant cells expressing CD47 and/or PD-L1 (e.g. cancer).
    Type: Application
    Filed: March 22, 2022
    Publication date: October 6, 2022
    Inventors: Xavier CHAUCHET, Krzysztof MASTERNAK, Limin SHANG, Elise PENARRIETA, Walter FERLIN
  • BISPECIFIC ANTIBODIES TARGETING CD47 AND PD-L1 AND METHODS OF USE THEREOF
    Publication number: 20220315655
    Abstract: This disclosure provides novel bispecific antibodies that specifically bind to CD47 and Programmed Death-Ligand 1 (PD-L1). The disclosure further relates to methods of making the bispecific antibodies and nucleic acids encoding the antibodies. The disclosure further relates to therapeutic methods for use of the bispecific antibodies in the treatment of a condition associated with malignant cells expressing CD47 and/or PD-L1 (e.g. cancer).
    Type: Application
    Filed: March 22, 2022
    Publication date: October 6, 2022
    Inventors: Xavier CHAUCHET, Krzysztof MASTERNAK, Limin SHANG, Giovanni MAGISTRELLI, Nicolas FISCHER